Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Free Report) have been given a consensus rating of “Hold” by the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $6.14.
Several research firms have recently commented on FHTX. Weiss Ratings raised shares of Foghorn Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, November 9th. Stifel Nicolaus set a $5.00 price target on shares of Foghorn Therapeutics in a report on Thursday, October 1st. Citizens Jmp cut shares of Foghorn Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 1st. TD Cowen downgraded Foghorn Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 1st. Finally, Guggenheim reduced their price objective on Foghorn Therapeutics from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, October 2nd.
View Our Latest Research Report on FHTX
Hedge Funds Weigh In On Foghorn Therapeutics
Several large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Foghorn Therapeutics during the 2nd quarter worth $12,819,000. Renaissance Technologies LLC raised its position in shares of Foghorn Therapeutics by 36.5% during the 1st quarter. Renaissance Technologies LLC now owns 406,425 shares of the company’s stock valued at $1,943,000 after acquiring an additional 108,689 shares during the last quarter. SCS Capital Management LLC acquired a new position in shares of Foghorn Therapeutics in the 2nd quarter valued at $522,000. Bank of New York Mellon Corp bought a new position in shares of Foghorn Therapeutics in the 2nd quarter worth $387,000. Finally, Empowered Funds LLC bought a new position in shares of Foghorn Therapeutics in the 3rd quarter worth $252,000. Institutional investors and hedge funds own 61.55% of the company’s stock.
Foghorn Therapeutics Stock Down 2.2%
Shares of NASDAQ FHTX opened at $1.79 on Monday. The firm’s 50-day simple moving average is $2.61 and its 200 day simple moving average is $4.46. The company has a market cap of $107.33 million, a price-to-earnings ratio of 25.58 and a beta of 3.22. Foghorn Therapeutics has a 12-month low of $1.73 and a 12-month high of $7.61.
Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $1.04. Foghorn Therapeutics had a net margin of 8.40% and a negative return on equity of 13.46%. The firm had revenue of $83.54 million during the quarter, compared to analysts’ expectations of $7.10 million. On average, equities analysts expect that Foghorn Therapeutics will post -0.07 earnings per share for the current year.
Foghorn Therapeutics Company Profile
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.
See Also
- Five stocks we like better than Foghorn Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
